• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

mRNA Brain Cancer Vaccine Shows Promise In Early Trials In Humans – And Dogs

May 1, 2024 by Deborah Bloomfield

A new mRNA vaccine candidate for aggressive brain cancer has shown promise in a small clinical trial – but it was a clinical trial with a twist. As well as testing the vaccine in a handful of human cancer patients, the researchers are also leveraging results from 10 pet dogs.

Advertisement

It’s very typical for drugs and treatments destined for human use to be trialed in animals first. Often, this stage of proceedings will come after experiments in cells in the lab, and before the drug gets near any human volunteers. While many efforts are underway to reduce animal testing and replace it with alternatives, it’s still a mainstay of pharmaceutical research.

Advertisement

Usually, though, we’re not actually trying to treat the animals for a disease they picked up naturally. Scientists develop models in species with organ systems that resemble the human equivalent, using drugs, surgery, or genetic modification to mimic the human disease. 

In the case of this mRNA vaccine, that part was completed in mice. But then there was another, more unusual step. It so happens that dogs are the only nonhuman species prone to the development of spontaneous brain tumors, so they offer an opportunity to test treatments in a more “natural” setting.

The owners of 10 pet dogs gave permission for their pooches to take part. This type of cancer, a glioma, is universally fatal, so this trial was the only treatment option available to them. Compared with the usual average survival time of 30-60 days after a diagnosis, the dogs lived for a median 139 days after their vaccine – time for lots more treats and belly rubs. 

After positive results in both the mice and the dogs, the team administered the vaccine to four human patients with glioblastoma. This is the most aggressive form of brain cancer, with a low survival rate. 

Advertisement

It’s still too early to fully understand the clinical effects of the vaccine, but we do know that all patients were either free of disease for longer or survived for longer than expected. The results are sufficiently promising that an expanded Phase I trial is now planned to include both children and adults.

How does the vaccine work?

As we’ve seen with other recent advances in this area, a big advantage of mRNA-based vaccines for cancer is that they can be personalized to each patient. The glioblastoma vaccine combines this with an innovative delivery system.

“Instead of us injecting single particles, we’re injecting clusters of particles that are wrapping around each other like onions, like a bag full of onions,” explained senior author Dr Elias Sayour of the University of Florida in a statement. “And the reason we’ve done that in the context of cancer is these clusters alert the immune system in a much more profound way than single particles would.”

We’ve all become more familiar with the idea of mRNA vaccines thanks to the COVID-19 pandemic, but the ways this works is slightly different. RNA is extracted from each patient’s own tumor cells and then repackaged in a lipid nanoparticle “costume”. When this is reinjected into the bloodstream, the immune system interprets it as a virus, priming it to respond to any remaining tumor cells as well. 

Advertisement

The personalization tailors the vaccine to each patient, maximizing its efficacy, while the delivery system boosts the immune system’s response time.

“In less than 48 hours, we could see these tumors shifting from what we refer to as ‘cold’ – immune cold, very few immune cells, very silenced immune response – to ‘hot,’ very active immune response,” Sayour observed. 

“The demonstration that making an mRNA cancer vaccine in this fashion generates similar and strong responses across mice, pet dogs that have developed cancer spontaneously and human patients with brain cancer is a really important finding, because oftentimes we don’t know how well the preclinical studies in animals are going to translate into similar responses in patients,” said co-author Dr Duane Mitchell.

Sayour added that the vaccine could slot in with other immunotherapies for a combined treatment. “I am hopeful that this could be a new paradigm for how we treat patients, a new platform technology for how we can modulate the immune system,” he said.

Advertisement

The study is published in the journal Cell. 

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. United employees receiving COVID-19 vaccine religious exemption face unpaid leave
  2. Stocks find fleeting relief in Evergrande deal; Fed looms
  3. Deere workers reject six-year labor contract
  4. Long Lost Shipwreck Found, Confirming Tragic Accounts Of How It Sank In 1894

Source Link: mRNA Brain Cancer Vaccine Shows Promise In Early Trials In Humans – And Dogs

Filed Under: News

Primary Sidebar

  • One Star System Could Soon Dazzle Us Twice With Nova And Supernova Explosions
  • Unethical Experiments: When Scientists Really Should Have Stopped What They Were Doing Immediately
  • The First Humans Were Hunted By Leopards And Weren’t The Apex Predators We Thought They Were
  • Earth’s Passage Through The Galaxy Might Be Written In Its Rocks
  • What Is An Einstein Cross – And Why Is The Latest One Such A Unique Find?
  • If We Found Life On Mars, What Would That Mean For The Fermi Paradox And The Great Filter?
  • The Longest Living Mammals Are Giants That Live Up To 200 Years In The Icy Arctic
  • Entirely New Virus Detected In Bat Urine, And It’s Only The 4th Of Its Kind Ever Isolated
  • The First Ever Full Asteroid History: From Its Doomed Discovery To Collecting Its Meteorites
  • World’s Oldest Pachycephalosaur Fossil Pushes Back These Dinosaurs’ Emergence By 15 Million Years
  • The Hole In The Ozone Layer Is Healing And On Track For Full Recovery In The 21st Century, Thanks To Science
  • First Sweet Potato Genome Reveals They’re Hybrids With A Puzzling Past And 6 Sets Of Chromosomes
  • Why Is The Top Of Canada So Sparsely Populated? Meet The “Canadian Shield”
  • Humans Are In The Middle Of “A Great Evolutionary Transition”, New Paper Claims
  • Why Do Some Toilets Have Two Flush Buttons?
  • 130-Year-Old Butter Additive Discovered In Danish Basement Contains Bacteria From The 1890s
  • Prehistoric Humans Made Necklaces From Marine Mollusk Fossils 20,000 Years Ago
  • Zond 5: In 1968 Two Soviet Steppe Tortoises Beat Humans To Orbiting Around The Moon
  • Why Cats Adapted This Defense Mechanism From Snakes
  • Mother Orca Seen Carrying Dead Calf Once Again On Washington Coast
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version